Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reported blockbuster topline results from its pivotal Phase 3 LUCIDITY trial.
The late-stage study evaluated avexitide – the pharmaceutical firm’s first-in-class GLP-1 receptor antagonist – in patients suffering from post-bariatric hypoglycemia (PBH).
Following the meteoric surge, Amylyx stock is trading at nearly 3x its price at the start of this year.
What the LUCIDITY trial data means for Amylyx stock
The LUCIDITY trial met its primary endpoint with strong statistical significance (p=0.000003) – demonstrating a massive 55% reduction in moderate-to-severe hypoglycemic events compared to placebo over 16 weeks.
Unlike standard GLP-1 agonists that lower blood sugar, avexitide acts as a GLP-1 blocker, curbing the dangerous post-meal insulin spikes experienced by post-bariatric surgery patients.
With roughly 160,000 Americans affected by PBH and zero FDA-approved treatments available, avexitide holds Breakthrough Therapy Designation and represents a potential $1.7 billion peak-sales opportunity.
AMLX shares ripped higher today because management plans to submit a New Drug Application (NDA) by year-end, setting up a potential 2027 commercial launch in a virtually competition-free niche.
Why AMLX shares are worth selling today
Despite the flawless clinical readout, smart money knows that bio-pharma rallies on binary Phase 3 wins are classic “sell-the-news” events.
Amylyx shares are still nursing the wound of the company’s late-stage ALS drug failure (Relyvrio) – which forced a market withdrawal in 2024 and wiped out product revenue.
Transitioning from a clinical-stage firm to a commercial operator requires immense capex to build out sales infrastructure, navigate payer coverage, and execute market education.
With a 2027 commercial timeline, AMLX faces a multi-quarter structural vacuum where revenue remains non-existent, but operational losses and commercialization burn will escalate rapidly.
Plus, locking in gains after a “single-day” 60%+ spike avoids the inevitable volatility and potential equity dilution associated with commercialization build-outs.
How to play Amylyx Pharmaceuticals at current price
Trading at a market cap nearing $3.76 billion following Tuesday’s pop, AMLX stock has already priced in near-perfect regulatory approval and seamless commercial deployment.
Wall Street is treating a niche, rare-disease GLP-1 antagonist market as a guaranteed blockbuster, but adoption delays and reimbursement hurdles in post-bariatric care are notorious execution risks.
Additionally, holding the stock through a year-long regulatory review leaves investors exposed to broader biotech sector drawdowns and FDA review delays.
All in all, while the science behind avexitide is sound, the current risk-reward ratio heavily favors taking profits off the table and reallocating capital into commercial-stage biotechs with established cash flows.
Investors should also note that analysts see Amylyx Pharmaceuticals’ rally as overextended as well.
While the consensus rating on the Cambridge-headquartered company remains Buy, the mean price target of about $34.36 is roughly in line with the price at which it’s trading at writing.
The post Amylyx stock soars on GLP-1 success: here’s why investors should sell appeared first on Invezz